- Published at
- by marketscreener.com
positive
positive
Biogen Announces First Patient Treated in RESPOND Study Evaluating Benefit of SPINRAZA (nusinersen) in Patients Treated With Zolgensma (onasemnogene abeparvovec)
The global Phase 4 RESPOND study will evaluate the efficacy and safety of SPINRAZA in patients with a suboptimal clinical response to ZolgensmaClinical and real-world experience have reported... | January 8, 2021